{
    "nctId": "NCT05871788",
    "briefTitle": "Biomarkers in Patients With Metastatic Breast Cancer",
    "officialTitle": "Biomarkers in Patients With Metastatic Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Identify the Number of Eligible Patients for Immunotherapy According to the Epidemiological and Biological Profile in Tunisia",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1600,
    "primaryOutcomeMeasure": "number of eligible patients for immunotherapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Age \u2265 18 years old.\n* Signed informed consent\n* Histological evidence of breast carcinoma.\n* Locally advanced (stage III inoperable) or metastatic (stage IV) carcinoma, the metastases of which have been diagnosed straight away or after adjuvant or neoadjuvant treatment.\n* No treatment for metastatic disease.\n* Metastatic disease: histological evidence of metastasis\n* Patients who will receive systemic treatment (chemotherapy, targeted therapy, hormone therapy)\n* Life expectancy greater than 3 months\n\nExclusion Criteria:\n\n* Non-epithelial breast cancer\n* Non-biopsiable metastases\n* Patients who have received before systemic treatment for metastatic disease (chemotherapy, targeted therapy, hormone therapy)\n* Patients with a contraindication to chemotherapy, and / or hormone therapy, and\n\n  / or targeted therapy.\n* Foreign patients",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}